Clinical Trial Update: Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating vatalanib in combination with octreotide for progressive neuroendocrine tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Carcinoid Tumor
• Islet Cell Carcinoma

Drugs mentioned

• OCTREOTIDE (OCTREOTIDE ACETATE)
• Vatalanib (vatalanib)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma | Phase 2 | Status: WITHDRAWN